U.S. Markets closed
  • S&P 500

    3,236.92
    -78.65 (-2.37%)
     
  • Nasdaq

    10,632.99
    -330.65 (-3.02%)
     
  • Russell 2000

    1,451.46
    -45.50 (-3.04%)
     
  • Crude Oil

    39.26
    -0.67 (-1.68%)
     
  • Gold

    1,857.00
    -11.40 (-0.61%)
     
  • Silver

    22.04
    -1.06 (-4.61%)
     
  • EUR/USD

    1.1659
    -0.0003 (-0.0233%)
     
  • 10-Yr Bond

    0.6760
    +0.0120 (+1.81%)
     
  • Vix

    28.58
    +1.72 (+6.40%)
     
  • GBP/USD

    1.2717
    -0.0009 (-0.0687%)
     
  • BTC-USD

    10,220.15
    -321.60 (-3.05%)
     
  • CMC Crypto 200

    207.71
    -6.26 (-2.92%)
     
  • FTSE 100

    5,899.26
    +69.80 (+1.20%)
     
  • Nikkei 225

    23,346.49
    -13.81 (-0.06%)
     

Aurinia Pharmaceuticals to Release First Quarter 2020 Financial Results on May 14, 2020

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the "Company") today announced that it will release its first quarter 2020 financial results on Thursday, May 14, 2020, after the markets close. Aurinia’s management team will host a conference call to discuss the Company’s financial results and to provide a general business update.

The conference call and webcast is scheduled for May 14, 2020 at 4:30pm ET. In order to participate in the conference call, please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

ABOUT AURINIA

Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company is currently developing the investigational drug voclosporin for the treatment of lupus nephritis, focal segmental glomerulosclerosis and dry eye syndrome. The Company’s head office is in Victoria, British Columbia and focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200507005282/en/

Contacts

Investors:
Glenn Schulman, PharmD, MPH
SVP, Corporate Communications & IR
gschulman@auriniapharma.com